On July 29, Teva Pharmaceutical rose 6.95% in regular trading, trading at $35.27/share, with turnover of $87.75 million. The rally was driven by the company's Q2 earnings release featuring above-consensus revenue and an upward revision to full-year guidance.

Teva reported Q2 net revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. The company simultaneously raised its full-year revenue guidance to $16.5 billion–$16.85 billion, up from the prior range of $16.4 billion–$16.8 billion, while reaffirming Non-GAAP EPS guidance of $1.91–$2.11. However, Q2 adjusted EPS came in at just $0.02, sharply missing the $0.25 estimate and representing a 97% year-over-year decline. Despite the earnings miss, the market prioritized the revenue beat and guidance upgrade as signals of sustained top-line momentum.

Supporting sentiment, Teva has advanced multiple pipeline and biosimilar initiatives in recent months, including a global licensing deal for an Ocrevus biosimilar, the European launch of Eylea biosimilar Ahzantive, submission of ecopipam NDA for pediatric Tourette syndrome, and a $400 million Blackstone-backed funding deal for duvakitug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)